iRadimed (IRMD) Stock Price, News & Analysis

Company Overview

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company’s core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites. These include safety filters, pressure transducers and patient temperature management systems, all optimized for operation within high-field magnetic environments. The company’s focus on reliability and regulatory compliance supports clinical use in hospitals, imaging centers and research institutions worldwide.

Founded in 1999 and headquartered in Winter Springs, Florida, iRadimed serves a global customer base through direct sales and international distributors across North America, Europe, Asia and Latin America. Its products are used in applications such as neuroimaging, cardiac imaging and oncology protocols where precise fluid delivery under MRI guidance is critical.

iRadimed completed its initial public offering in 2011 and is traded on the NASDAQ under the symbol IRMD. John B. Reininga, the company’s founder, serves as President and Chief Executive Officer, guiding product innovation and strategic growth in the specialized field of MRI-compatible medical devices.

Key Stats

• Today's Range: $91.37 to $95.47
• 50-Day Range: $83.44 to $102.80
• 52-Week Range: $50.88 to $107.90
• Volume: 142,240 shs
• Average Volume: 93,268 shs
• Market Capitalization: $1.18 billion
• P/E Ratio: 50.33
• Dividend Yield: 0.87%
• Price Target: $120.00
• Consensus Rating: Buy

iRadimed Stock Analysis - MarketRank™

iRadimed scored higher than 52% of companies evaluated by MarketBeat, and ranked 477th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Buy

Consensus Rating

iRadimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, 3 buy ratings, 1 hold rating, and no sell ratings.

Upside Potential

iRadimed has a consensus price target of $120.00, representing about 30.3% upside from its current price of $92.10.

Amount of Analyst Coverage

iRadimed has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of iRadimed is 50.33, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.94.

Price to Earnings Ratio vs. Sector

The P/E ratio of iRadimed is 50.33, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 20.99.

Price to Book Value per Share Ratio

iRadimed has a P/B Ratio of 11.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

6.77% of the float of iRadimed has been sold short.

Short Interest Ratio / Days to Cover

iRadimed has a short interest ratio ("days to cover") of 5.35.

Change versus previous month

Short interest in iRadimed has recently increased by 1.27%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

iRadimed has a dividend yield of 0.88%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

iRadimed has only been increasing its dividend for 1 years.

Dividend Coverage

The dividend payout ratio of iRadimed is 43.72%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: -0.43

News Sentiment

iRadimed has a news sentiment score of -0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for iRadimed this week, compared to 3 articles on an average week.

Search Interest

3 people have searched for IRMD on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

MarketBeat Follows

1 people have added iRadimed to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 2.1 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, iRadimed insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,318,853.00 in company stock.

Percentage Held by Insiders

36.80% of the stock of iRadimed is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

92.34% of the stock of iRadimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Record date for 3/6 Dividend: 2/23/2026
• Ex-Dividend for 3/6 Dividend: 2/23/2026
• Dividend Payable: 3/06/2026
• Last Earnings: 5/01/2026
• Record date for 5/29 Dividend: 5/15/2026
• Ex-Dividend for 5/29 Dividend: 5/15/2026
• Today: 5/22/2026
• Dividend Payable: 5/29/2026
• Next Earnings (Estimated): 7/30/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED INSTRUMENTS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:IRMD
• CIK: 1325618
• Web: www.iradimed.com
• Phone: (407) 677-8022
• Fax: 407-677-5037
• Employees: 110
• Year Founded: 2004

Price Target and Rating

• Average Price Target for iRadimed: $120.00
• High Price Target: $120.00
• Low Price Target: $120.00
• Potential Upside/Downside: +30.3%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.83
• Trailing P/E Ratio: 50.33
• Forward P/E Ratio: 60.59
• P/E Growth: N/A
• Net Income: $22.48 million
• Net Margins: 27.36%
• Pretax Margin: 34.98%
• Return on Equity: 24.48%
• Return on Assets: 21.25%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.13
• Quick Ratio: 6.15

Sales & Book Value

• Annual Sales: $83.81 million
• Price / Sales: 14.04
• Cash Flow: $1.89 per share
• Price / Cash Flow: 48.63
• Book Value: $7.71 per share
• Price / Book: 11.95

Miscellaneous

• Outstanding Shares: 12,780,000
• Free Float: 8,079,000
• Market Cap: $1.18 billion
• Optionable: Optionable
• Beta: 0.90